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COSMECEUTIQOL: A DERMO-COSMETIC QUALITY-OF-LIFE ASSESSMENT TOOL
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OBJECTIVES: For over 40 years, “dermo-cosmetics”, or “cosmeceuticals”, have been
identified with the field of cosmetics and hygiene products adhering to the rules of
good practice of pharmaceutical science. Paradoxically, while “dermo-cosmetics”,
or “cosmeceuticals”, are developing and now concern all age groups of the popu-
lation, there is no quality-of-life questionnaire available to assess the impact of this
treatment on quality of life.The evaluation of its impact in terms of quality of life is
however a bold, ambitious and also necessary step. The CosmeceutiQoL has ar-
rived to fill this gap. . The objective of this evaluation was to test the Cosmeceu-
tiQoL’s sensitivity to change in women using a dermo-cosmetic. METHODS:
Women aged 22 to 66y and users of Tolerance Extreme DEFI were recruited in
French pharmacies. They completed the CosmeceutiQoL on inclusion and on the
7th and 14thday. An irritability and Sensiscale score were also taken. RESULTS:
Fourty-four women aged 22 to 66y, 72% report using day cream, 42% a night cream.
The irritability score, measured using a visual analog scale, was 4.2 at baseline.
Sensitivity, measured using the Sensiscale, was 43.3 at baseline. The Cosmeceu-
tiQoL score was 42.5.On the 7th and 14thday, the irritability score was 2.39 and 1.23
and the Sensiscale was 19.80 and 7.03 respectively. During the same time interval,
the CosmeceutiQoL scores were 53 and 71. For the three scores, there was a statis-
tically significant improvement in the score from the 7th day. This improvement
was confirmed on the 14th day. There were no significant differences according to
the patient’s age. CONCLUSIONS: The CosmeceutiQoL questionnaire was created
and validated in 2010. Its objective was to assess a dermo-cosmetic’s impact on the
quality-of-life of women. The significant improvement in the score from the 7th
day, maintained on the 14thday, confirms the relevance of this questionnaire.The
CosmeceutiQoL’s reproducibility was confirmed during questionnaire validation,
and this evaluation validates sensitivity to change.
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PREVALENCE OF CHRONIC WOUNDS IN GERMANY — A SECONDARY DATA
ANALYSIS
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OBJECTIVES: Since in Germany no population-based results of the frequency of
chronic wounds are available, the prevalence of chronic wounds was computed
using routine statutory health insurance data. METHODS: Data on medical care in
all health-service sectors, i.e. stationary and ambulant care, drug and remedy pre-
scriptions, of patients with chronic wounds of a national statutory health insur-
ance (Deutsche Angestellten-Krankenkasse) based on approximately 6.3 Million
members covering the years 2007/08 were available. Chronic wounds were identi-
fied by a priori specified ICD-10 diagnoses. Organized data of statutory health in-
surance, originally assessed for panel doctors’ clearings, require a high effort to be
converted into a format suitable for scientific analysis. Data records were checked
iteratively for integrity and plausibility. As chronic wounds are more frequent in
older age groups, prevalence rates for the insurants have to be adjusted for age and
sex to consign them to the German general population. Moreover subgroup anal-
yses were conducted for year and diagnoses, confidence intervals were calculated.
RESULTS: Approximately 178 Million data records were merged. Data quality
proofed to be good and sufficient for reliable analyses. Based on approximately 158
000 patients with chronic wounds a prevalence rate of 1.61% (1.60-1.62) was calcu-
lated for 2007, 1.70% (1.68-1.70) for 2008. The increase over time also appeared for
diagnostic subgroups, e.g. ulcus cruris increases from 0.99% (0.98-1.00) to 1.02 (1.01-
1.03). Higher rates in the elderly were also confirmed. The highest sex-adjusted rate
was observed for ulcus cruris in patients aged 90 or older (11.05%). CONCLUSIONS:
Data of statutory health insurances offer a high potential for health services re-
search. Because of the high number of cases and adjustable demographic factors
the data can be used for calculation of population based prevalence rates and can
be compared to other studies, different diagnoses, health systems and geographi-
cal regions.
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PREDICTORS OF BIOLOGIC TREATMENT IN PSORIASIS POPULATION
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OBJECTIVES: Significant advances have been made in treatment of psoriasis with
advent of biologic therapies. However, no studies to date have examined predictors
of biologic treatment. Based on analyses of the Adelphi Disease Specific Pro-
gramme database for Psoriasis (2007), the authors examined predictors and patient
characteristics of biologic treatment for Psoriasis patients in Spain, France and UK.
METHODS: Current biologic users were defined as having three previous regimens
of non-biologic use and current regimen was reported as biologic treatment. Bio-
logic treatment included infliximab, etanercept, and adalimumab. Non-biologic
users demonstrated no biologic treatment use in three previous and one current
regimen. Patients whose current severity characterized as Moderate-Severe had a
mean PASI Score  10. Mild patients had a mean PASI score  10. RESULTS:
Analyses revealed that greater proportion of biologic users were obese by BMI and
have nail and joint involvement versus non-biologic users. For Spain, France and
the UK, 18%, 23% and 23% of current biologic users were obese vs 7%, 9% and 0% for
non-biologic users. 49%, 66%, 45% of current biologic users vs 25%, 23%, 100% of
non-biologic users had nail involvement and 24%, 36%, 15% of current biologic
users vs 8%, 11%, 50% of non-biologic users had joint involvement or psoriatic
arthritis. Findings did not reach statistical significance. Logistic regression models
adjusting for age, gender, and PASI Score demonstrated statistically significant
increased odds of being current biologic user vs. non-biologic user if patient had
health insurance for biologic treatment. Spain: OR 43.6 (95% CI: 13.4 – 142.1);
France, OR 26.8 (95%CI: 7.0-73.2);UK, OR  3.9 (95% CI: 1.01 – 15.21). Percentage of
patients with health insurance for biologic treatment were: 40%, 31%, and 2.5%.
CONCLUSIONS: Lack of health insurance is an important predictor of current bio-
logic treatment, since moderate-severe patients who demonstrate increased nail
and joint involvement, may not receive adequate treatment due to lack of health
insurance.
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TREATMENT PATTERNS OF BIOLOGIC USE IN PSORIASIS PATIENTS IN
ENGLAND
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OBJECTIVES: To describe biologic treatment patterns and effectiveness among pa-
tients with psoriasis who initiated biologic therapy in dermatology clinics in
England.METHODS:A chart review was conducted using a sequential cohort of 169
patients with psoriasis 18 years of age from six dermatology clinics. Data were
abstracted for patients newly initiating biologic treatment between 1 July 2005 and
30 June 2009. Severity was measured by the Psoriasis Area and Severity Index (PASI,
range: 0 to 72) at baseline and time of treatment change. Higher scores indicated
increased severity (score 10 indicates moderate to severe disease); adequate re-
sponse was defined by a75% reduction. Biologic treatment patterns in the first 12
months following initiation (discontinuation, switching, dose increase, and persis-
tence), including reason for treatment change, were collected. RESULTS: Average
age at biologic initiation was 49 years, 59.5% were male, with mean disease dura-
tion of 15 years. Mean (SD) PASI score at initiation was 18.4 (7.8). Eighteen percent
of patients discontinued biologic use, 12% switched, and 7% increased their bio-
logic dose within the first 12 months. Patients who persisted on initial biologic
therapy (63%) achieved an average PASI score of 3.9 (78% improvement) at 12
months. When lack of effectiveness was cited at time of discontinuation, the mean
PASI score was 22.6 (43% increase). Among patients who switched, the mean PASI
was 15.7 (24% reduction) at the time of switch. In those who increased their dose,
mean PASI score was 9.4 (52% reduction) at the time of dose increase.
CONCLUSIONS: A large proportion (37%) of patients changed or discontinued bio-
logic therapy due to an inadequate response to initial treatment within the first
year. These patients experienced limited PASI response and PASI scores were
found to be high at time of treatment change, suggesting an unmet need exists for
this population.
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TREATMENT PATTERNS: AN ON-LINE STUDY OF ECZEMA PATIENTS
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OBJECTIVES: To better understand care patterns and quality of life amongst ec-
zema patients and explore potential differences associated with dermatologist
access.METHODS:UK patients were invited to complete an on-line screener for the
study based on: self-reported eczema, use of Rx/OTC treatment, and consultation
with a doctor. Eligible subjects proceeded to a 32 question survey; successful com-
pleters received £10. RESULTS: We screened 258 adults to obtain 100 completed
surveys between 25 May and 1 June. Although 65% were diagnosed 10 years ago,
74% report it is difficult, very difficult, or extremely difficult to manage their con-
dition. Eczema has a very or extremely large effect on a patient’s life for 41%; an
additional 32% experience a moderate effect based on the Dermatology Quality of
Life Index. 69% of respondents report asking their GP for referral to a dermatologist,
but 47 of 69 were ultimately referred (68%). While there are some similarities be-
tween GP and dermatology visits (e.g., description of medicine and associated side
effects), individuals visiting a dermatologist report: longer visit duration (68% spent
10 minutes vs. 10% GP, p0.001); discussions of eczema cause (62% Derm vs.
30% GP, p 0.0012); description of eczema symptoms (68% Derm vs. 38% GP,
p0.0018); and training on moisturizer application (94% Derm vs. 64% GP,
p0.0007). Although differences in care exist, there was no apparent difference in
severity between those patients referred vs. not referred to a dermatologist, nor
was there an apparent difference in education, age, gender, income or employment
status. CONCLUSIONS: This study demonstrates the impact of eczema on patient
QoL, and differences in management between GPs and dermatologists highlighted
by more education by dermatologists. Previous studies have demonstrated that
more education leads to better outcomes. Standardising referral guidelines by in-
cluding the DLQI may lead to more appropriate referrals and optimized patient
management.
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